Alkermes to Report First Quarter Financial Results on April 27, 2022
Alkermes plc (Nasdaq: ALKS) will host a conference call on April 27, 2022, at 8:00 a.m. ET to discuss its first quarter financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will host a conference call on April 27, 2022, at 8:00 a.m. ET to discuss its first quarter financial results. The call will provide updates on the company's performance and future outlook. Investors can access the live webcast and slides through the Alkermes website. For participation, U.S. callers can dial +1 877 407 2988, while international callers can use +1 201 389 0923. A replay of the event will be available shortly after its conclusion.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was -0.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, April 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 27, 2022 to discuss the company's first quarter financial results. Management will also provide an update on the company.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Alex Braun
Investor Relations
+1 781 296 8493
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-first-quarter-financial-results-on-april-27-2022-301529145.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.